Indeed, pharmacologic blockade of IL6 in a mouse model of KRAS-mutant lung cancer results in a reduction in protumorigenic macrophages and Tregs with concomitant activation of CD8+ T cells (41). Here, KRAS is linked to lung carcinoma.